Patrick Zenner - West Pharmaceutical Independent Chairman of the Board
| WST Stock | USD 228.68 1.17 0.51% |
Chairman
Mr. Patrick J. Zenner is Independent Chairman of the Board of the West Pharmaceutical Services, Inc. Mr. Zenner was elected Chairman of the Board effective July 1, 2015. He retired from HoffmannLa Roche Inc., North Americathe prescription drug unit of the Roche Group, a leading researchbased healthcare enterprisein 2001, where he served as President and Chief Executive Officer from 1993 to 2001. He served as Interim Chief Executive Officer of CuraGen Corporation from May 2005 through March 2006. Since then, Mr. Zenner was a director and Chairman of the Board of Exact Sciences Corporation until July 2010 and served as its Interim CEO from July 2007 to March 2008. Currently, Mr. Zenner serves as Chairman of the Board of ArQule, Inc. and as a director of Selecta Biosciences, Inc. Mr. Zenner is currently a member of the Board of Trustees of Creighton University and is Chairman of the Board of Trustees of Fairleigh Dickinson University. since 2015.
| Age | 73 |
| Tenure | 10 years |
| Address | 530 Herman O. West Drive, Exton, PA, United States, 19341-1147 |
| Phone | 610 594 2900 |
| Web | https://www.westpharma.com |
West Pharmaceutical Management Efficiency
The company has Return on Asset of 0.0993 % which means that on every $100 spent on assets, it made $0.0993 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1771 %, implying that it generated $0.1771 on every 100 dollars invested. West Pharmaceutical's management efficiency ratios could be used to measure how well West Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, West Pharmaceutical's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.14 in 2025, whereas Return On Capital Employed is likely to drop 0.10 in 2025. At this time, West Pharmaceutical's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 3.8 B in 2025, whereas Non Current Liabilities Total is likely to drop slightly above 311.4 M in 2025.Similar Executives
| Found 14 records | CHAIRMAN Age | ||
| Liam Kelly | Teleflex Incorporated | 58 | |
| Vivek Jain | ICU Medical | 53 | |
| D Grossman | Alcon AG | 60 | |
| Thomas Polen | Becton Dickinson and | 52 | |
| Vincent Forlenza | Becton Dickinson and | 66 | |
| Michael Ball | Alcon AG | 70 | |
| Jose Almeida | Baxter International | 63 | |
| Richard Meelia | Haemonetics | 71 | |
| Peter Farrell | ResMed Inc | 78 | |
| Stephen MacMillan | Hologic | 61 | |
| Ronald Gelbman | Haemonetics | 70 | |
| Fred Lampropoulos | Merit Medical Systems | 75 | |
| Ellen Zane | Haemonetics | 69 | |
| Allan Rubenstein | The Cooper Companies, | 74 | |
Management Performance
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0993 |
West Pharmaceutical Leadership Team
Elected by the shareholders, the West Pharmaceutical's board of directors comprises two types of representatives: West Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of West. The board's role is to monitor West Pharmaceutical's management team and ensure that shareholders' interests are well served. West Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, West Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Buthman, Independent Director | ||
| Deborah Tanner, Independent Director | ||
| Bernard Birkett, Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer | ||
| Eric Green, President, Chief Executive Officer, Director | ||
| John CFA, Head Relations | ||
| Rudy Poussot, Senior Development | ||
| Kathy DePadua, Senior Officer | ||
| Dr CFA, Vice Relations | ||
| William Feehery, Independent Director | ||
| Aileen RuffPatry, President Manufacturing | ||
| Robert Friel, Independent Director | ||
| Richard Luzzi, VP HR | ||
| Myla LaiGoldman, Independent Director | ||
| Paula Johnson, Independent Director | ||
| Douglas Michels, Independent Director | ||
| Michele Polinsky, Vice Communications | ||
| Kimberly MacKay, Senior Vice President General Counsel, Corporate Secretary | ||
| Don OCallaghan, President Devices | ||
| Paolo Pucci, Independent Director | ||
| Annette Favorite, Chief Human Resource Officer, Senior Vice President | ||
| Patrick Zenner, Independent Chairman of the Board | ||
| Thomas Hofmann, Independent Director | ||
| Silji Abraham, Senior Vice President and Chief Digital and Transformation Officer | ||
| David Montecalvo, Senior Vice President, Chief Operating and Supply Chain Officer | ||
| Christopher Ryan, Senior Vice President of Commercial Products and Emerging Markets | ||
| Quintin Lai, Vice President - Corporate Development, Strategy and Investor Relations | ||
| Molly Joseph, Director | ||
| Andy Polywacz, President Systems | ||
| George Miller, Senior Vice President General Counsel, Corporate Secretary | ||
| Charles CPA, VP Treasurer | ||
| Cindy ReissClark, Senior Vice President of Global Market Units and Commercial Solutions | ||
| Chad Winters, Chief Accounting Officer, Principal Accounting Officer, Vice President, Corporate Controller | ||
| Robert Segura, VP Devel | ||
| Eric Resnick, Chief Technology Officer, Vice President |
West Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is West Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0993 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 16.27 B | ||||
| Shares Outstanding | 72.3 M | ||||
| Shares Owned By Insiders | 0.59 % | ||||
| Shares Owned By Institutions | 97.33 % | ||||
| Number Of Shares Shorted | 1.37 M | ||||
| Price To Earning | 40.71 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for West Stock Analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.